Serhii Pavlovich Prilutskyi, born on November 13, 2000, in Cherkassy, Ukraine, graduated with a Master of Biology (MS) degree from Melitopol State University Pedagogical University, where he studied from September 1, 2017, to December 31, 2022. Throughout his career, Serhii gained valuable experience working with the international pharmaceutical company "Yuriya-Pharm" and the private clinical research company "SMO YUST." His education and work experience have equipped him with a strong foundation in biology and research, preparing him for future contributions to the field.
Scientific interest: virology, human genetics, theoretical and clinical medicine, radiobiology, genetic engineering and therapy, CRISPR/Cas genome editing technology
EFFICIENCY OF RETROVIRAL GENE THERAPY IN THE TREATMENT OF SEVERE COMBINED IMMUNODEFICIENCY
Prilutsky S.P. M.S. Biology Melitopol State Pedagogical University, Zaporozhye, Ukraine Introduction. Incurable diseases affecting various anatomical and physiological systems of the human body are an important problem of modern biomedicine, which actualizes the search for reliable and effective methods of their treatment. However, at the current stage of development of biotechnology and genetic engineering, gene therapy using viral vectors is a relevant method in the treatment of incurable diseases. Objectives. To analyze the effectiveness of using retroviral gene therapy as a potential method in the treatment of severe combined immunodeficiency based on the available published literature. Methods. Analysis of literary sources Results. Recombinant retrovirus strains are most often used as vectors for the delivery of correction genes due to the expression of viral genes of reverse transcriptase enzymes that allow the synthesis of DNA genome from RNA and integrase for promotion in the genome of the host target cell, thereby demonstrating their effectiveness in the result of mass pathological conditions. Such effectiveness is the study of local scientists who found that after receiving gammaretroviral vector cDNA ADA covers patients with severe combined immunodeficiency (SCID) in autologous T cells, gradual homeostasis of purine metabolism was observed with further restoration of immune function without causing factors for patients within 13 years after the introduction of the example virus. Subsequent studies in SCID using gammaretroviral vectors to activate wild-type IL2RG gene expression for transduction of HSPC in patients with SCID-X1. Despite the regeneration of the immune system in 100% of patients after treatment, 30% of them showed multiple effects in the form of activation of expression of proto-oncogenes LMO2, CCND2, MECOM, thus most provoking the development of the acute phase of leukemia. Conclusion. The German experience shows the effectiveness of using the retrovirus method as a means of therapeutic delivery of the ADA gene to the reservoir of patients with SCID. However, the factors demonstrate some consequences after treatment, such as activation of expression of some proto-oncogenes. Perhaps this is due to the effect on other defective genes IL2RG or IL7R, which are also mutant in the pathogenesis of SCID. Key words: gammaretrovirus, SCID, T cells